530549: Global Expansion Will Accelerate With Upcoming Product Launches

Shilpa Medicare's analyst price target remains unchanged at ₹514.5, as analysts continue to reaffirm their estimates based on stable forecasts for the company’s growth and profitability metrics. What's in the News Shilpa Medicare Limited will hold a Special/Extraordinary Shareholders Meeting via postal ballot on November 8, 2025 (company announcement).

Analysts have raised their price target for Shilpa Medicare marginally from ₹514.25 to ₹514.50, citing a slightly improved profit margin outlook and steady revenue growth expectations. What's in the News Shilpa Medicare secured regulatory approval from India's Central Drugs Standard Control Organization for Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg.

Analysts have revised Shilpa Medicare’s fair value price target substantially downward from ₹1,028.50 to ₹514.25. This change reflects updated projections and a reassessment of expected performance metrics.

Shilpa Medicare's consensus price target has increased to ₹1028, driven primarily by a notable rise in its future P/E multiple despite a slight decline in net profit margin. What's in the News Secured world's first CDSCO approval for NorUDCA Tablets 500mg, the first therapy targeting NAFLD; plans rapid commercialization in India and pursuit of global regulatory pathways.

AnalystConsensusTarget has decreased future PE multiple from 23.1x to 18.0x and increased shares outstanding growth rate from 0.1% to 0.1%.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget has increased future PE multiple from 18.3x to 23.1x.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget has increased revenue growth from 32.5% to 37.0% and decreased future PE multiple from 26.7x to 18.3x.